Vertex, Molecular Templates partner to improve conditioning regimens for edited cell therapies

Vertex is collaborating with Molecular Templates to establish more targeted conditioning regimens that could replace chemotherapy in patients undergoing hematopoietic stem cell transplants.

Under the deal, Molecular Templates Inc. (NASDAQ:MTEM) will use its engineered toxin body (ETB) technology to discover and develop ETBs against up to two targets chosen by Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) to ablate specific cells in patients receiving HSCTs, including those being treated with Vertex's CTX001. ...